GlobeNewswire

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Share
  • Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1
  • Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up to five years2
  • Results from EXCHANGE interim analysis presented at ACTRIMS-ECTRIMS reinforced its safety and tolerability profile when patients switched from an oral or injectable disease-modifying therapy (DMT) to Mayzent3

The digital press release with multimedia content can be accessed here:

Basel, September 11, 2020 — Novartis announced today that Mayzent® (siponimod) analyses from the Phase IIIb EXCHANGE and EXPAND trials showed Mayzent to be a safe treatment option that has benefits in cognitive performance and reduces the risk of disability progression in patients with progressing MS1-3. The data were presented at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting that is taking place September 11–13, 2020.

“One of the biggest goals for people living with MS is to be able to live their lives independently for as long as possible," said Norman Putzki, MD, Global Head of Development, Neuroscience. “The data presented today reinforces that through its beneficial effects on cognitive performance and delaying disability progression, and as an appropriate option for patients to safely switch to/from other treatments, Mayzent offers hope for people looking to achieve this important goal.”

The EXCHANGE study is a Phase IIIb prospective, six-month open-label study evaluating the safety and tolerability of conversion to Mayzent from other disease-modifying therapies (DMTs) in patients with relapsing multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS). The interim analysis included 112 patients from 42 centers in the US who were eligible for the safety analysis3. The EXPAND study is a randomized, double-blind, placebo-controlled Phase III study, comparing the efficacy and safety of Mayzent versus placebo in patients with SPMS with varying levels of disability. The post hoc EXPAND analysis found that in patients with active disease, an increased chance for clinically relevant improvement was observed and patients with active SPMS early and continuously treated with Mayzent experienced lower risk of disability progression and cognitive decline than patients who delayed Mayzent treatment1,2.

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References
1.    Penner IK, Giovannoni G, Cree B, et al. Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease. ePoster presentation at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting; September 2020
2.    Giovannoni G, Kappos L, Fox RJ, et al. Sustained reduction of disability and cognitive decline with long-term siponimod treatments in patients with active SPMS: EXPAND data up to 5 years. ePoster presentation at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting; September 2020
3.    Bar-Or A, Weinstock-Guttman B, Mao-Draayer Y, et al. Safety and tolerability of conversion to siponimod in patients with relapsing multiple sclerosis: interim results of the EXCHANGE study. ePoster presentation at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting; September 2020

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Antonio Ligi
Novartis External Communications
+41 79 723 3681 (mobile)
antonio.ligi@novartis.com



Eric Althoff
Novartis US External Communications
+1 862 778 3243
+1 646 438 4335
eric.althoff@novartis.com
Michael Amos
Novartis Global Pharma Communications
+41 61 324 2705 (direct)
+41 79 123 7806 (mobile)
michael.amos@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Thomas Hungerbuehler 
Isabella Zinck
+41 61 324 8425
+41 61 324 7188

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GOGL – Notice of Annual General Meeting 202120.4.2021 22:14:11 CEST | Press release

Golden Ocean Group Limited (the “Company”) announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2020 can be found on our website at www.goldenocean.bm and in the links below. April 20, 2021 The Board of Directors Golden Ocean Group Limited Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments GOGL - 2020 Form 20-FGOGL - Notice of Annual General Meeting 2021

RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR20.4.2021 20:10:00 CEST | Press release

Rapala VMC Corporation Stock Exchange Release April 20, 2021 at 9:10 p.m. RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR Rapala VMC Corporation’s outlook for 2021 has improved as a result of stronger than anticipated financial performance during the first three months of the year as well as upgraded positive business outlook for the remaining part of the year. The Group now expects full year 2021 comparable operating profit to increase significantly from the previous year. Key drivers behind the upgraded outlook are exceptionally strong winter sales, strong continued demand for fishing gear as it remains a popular COVID-safe activity globally as well as faster than expected strategy implementation. Uncertainties however remain for the rest of the year and the COVID-19 pandemic continues to pose some risks for the full-year performance. The pandemic can impact the oper

Korrigering till kallelse till Nexstim Abp:s bolagsstämma20.4.2021 20:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors, 20.4.2021 kl.21.00 (EEST) Korrigering till kallelse till Nexstim Abp:s bolagsstämma Aktieägarna i bolaget har med en stämmokallelse av 15 april 2021 kallats till Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) bolagsstämma som hålls 11 maj 2021 klockan 12.00 (EEST). Stämmokallelsen innehåller ett skrivfel enligt vilket den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdeandelskontona troligen senast 17 maj i Sverige och 19 maj i Finland. Oaktat det ovannämnda utförs och antecknas överföringen på värdeandelskontona troligen senast 17 maj i Finland och 19 maj i Sverige. Punkt A.15. i kallelsen till extra bolagsstämman har således ändrats som följer (ändringarna i fet stil): Den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdean

Correction to the Invitation to the Annual General Meeting of Nexstim Plc20.4.2021 20:00:00 CEST | Press release

Company announcement, Helsinki, 20.4.2021 at 9:00 pm (EEST) Correction to the Invitation to the Annual General Meeting of Nexstim Plc In accordance with the invitation to the Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") dated 15 April 2021, the shareholders of the Company have been invited to the Annual General Meeting to be held on 11 May 2021 commencing at 12.00 (EEST). The invitation to the meeting of 15 April 2021 includes a writing error stating that transfers of shares from the Company to the Receiving Shareholders required for the final adjustments of their number of shares (after reduction) are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Sweden and 19th May 2021 in Finland. Notwithstanding the above-mentioned, the transfers of shares are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Finland and 19th May 2021 in Sweden. Consequently, it w

MSAB publicerar årsredovisning för 202020.4.2021 20:00:00 CEST | Pressemelding

MSABs årsredovisning för 2020 finns nu tillgänglig på bolagets hemsida, www.msab.com/investerare/finansiella-rapporter/, samt bilagt detta pressmeddelande. Tryckt version kommer att finnas tillgänglig inom kort och kan beställas hos bolaget per telefon + 46 (0) 8 739 02 70 eller per e-post info@msab.com. I moderbolagets resultaträkning har en utdelning erhållits från ett av bolagets utländska dotterbolag om 5.5 MSEK, vilket ej var inkluderat i bolagets bokslutskommuniké. Frågor ställs till: Verkställande direktör Joel Bollö, tel. 08-739 02 70, e-mail: joel.bollo@msab.com Denna information är sådan som MSAB, 556244-3050, är skyldigt att offentliggöra enligt lagen (2007:528) om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 20 april 2021 klockan 20:00 CEST. Om MSAB MSAB är världsledande inom kriminalteknik för att utvinna och analysera data i beslagtagna mobila enheter. Företaget utvecklar högkvalitativ och lättanvänd mju

Flex LNG - AGM Notice20.4.2021 20:00:00 CEST | Press release

Flex LNG Ltd. (the "Company") announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F can be found in the links below and on our website at www.flexlng.com. April 20, 2021 The Board of Directors Flex LNG Limited Hamilton, Bermuda This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act or the Continuing Obligations of Oslo Børs. Attachments FLEX LNG - 20F 20202021 AGM Notice _FLEX (signed)

Banque Profil de Gestion SA : Assemblée Générale du 20 avril 202120.4.2021 18:04:22 CEST | Press release

Communiqué de presse Banque Profil de Gestion SA : Assemblée Générale du 20 avril 2021 Genève, le 20 avril 2021 – Lors de l’Assemblée Générale Ordinaire de la Banque Profil de Gestion SA (SIX Swiss Exchange : BPDG) qui s’est tenue aujourd’hui à Genève, 64.02% des actionnaires étaient représentés. Les actionnaires ont pris les décisions suivantes : Le rapport annuel et les comptes au 31 décembre 2020 ont été approuvés ;La pleine décharge a été donnée aux administrateurs de BPDG pour leur gestion durant l’exercice 2020 ;La couverture de la perte statutaire de CHF 2'336'667 avec la réserve légale issue du bénéfice a été approuvée ;Le versement d’un dividende de CHF 8'000'000 prélevé sur les réserves, soit un montant approximatif de CHF 0.5544 par action a été approuvé ;Madame Geneviève Berclaz, Monsieur Mario Aragnetti Bellardi, Monsieur Fabio Candeli, Monsieur Fulvio Pelli et Monsieur Fréderic Binder ont été réélus individuellement en qualité d’administrateur pour une durée de fonction d